Mechanism of action via opioid receptors
Classic drugs such as codeine act as agonists of opioid receptors in the digestive tract. By binding to these receptors, they trigger a cascade of reactions that fundamentally alter gastrointestinal function.
First, codeine specifically affects the muscular apparatus: it significantly enhances segmental (spasmodic) motility while suppressing propulsive peristalsis, which is normally responsible for moving the food bolus forward. Second, the drug increases the baseline tone of the intestinal smooth muscle and its sphincters. Third, codeine interferes with secretory function, actively inhibiting the secretion of water and electrolytes into the intestinal lumen.
The ultimate result of all these processes is a pronounced slowing of chyme transit through the intestine. However, codeine is able to cross the blood-brain barrier, which limits its use exclusively as an antidiarrheal agent.
Synthetic agonists (safe alternative)
This section of pharmacology focuses on drugs that inhibit intestinal motility, with a primary emphasis on their safety profile compared to classical opiates (such as morphine or codeine).
A prominent representative of this group is loperamide (trade name — Imodium). It is a synthetic opioid receptor agonist whose antidiarrheal action is completely analogous to codeine (decreased motility). However, its pharmacokinetics have fundamental differences. Loperamide has virtually no effect on the central nervous system because it is physically unable to accumulate behind the blood-brain barrier (BBB). The reason lies in the fact that the loperamide molecule is a substrate for P-glycoprotein. This transporter protein acts as a pump, continuously "pumping" the drug out of brain tissues back into the systemic circulation. Consequently, loperamide does not cause tolerance or drug dependence. Potential side effects of therapy include nausea, dizziness, and predictable constipation.
Another drug in this group is nufenoxole. Its basic mechanism of action is similar to loperamide, but the specific clinical effect is shifted towards fluid regulation. Nufenoxole predominantly inhibits the secretion of water and salts into the GI lumen while simultaneously enhancing the absorption (reabsorption) of fluid from the contents of both the small and large intestine.
Peripheral opioid receptor antagonists
In clinical practice, physicians frequently encounter the flip side of opioid action — severe constipation. This problem is particularly relevant for cancer patients receiving palliative therapy with potent narcotic analgesics.
Methylnaltrexone is used to treat such conditions. Chemically, it is an analog of naltrexone with one critically important feature: methylnaltrexone absolutely does not cross the blood-brain barrier.
Its pharmacological significance lies in the fact that it selectively blocks opioid receptors only in the periphery — directly within the intestinal wall. This restores normal peristalsis and relieves constipation without affecting the central analgesic action of opioids, which is vital for patients receiving palliative care.
Briefly: answers to topical questions
Which pharmacological groups are included in the classification of antidiarrheal agents, aside from opioid receptor agonists?
In addition to opioid receptor agonists, sources mention enterosorbents, as well as intestinal anti-inflammatory and antimicrobial agents (ATC code A07).
To avoid confusing the drugs: Codeine enters both the brain and the intestine. Loperamide goes only to the intestine (P-glycoprotein acts as a "bouncer" at the entrance to the brain). And Methylnaltrexone saves the intestine from opioid-induced constipation without touching analgesia in the brain.
Class and exam questions
Why doesn't loperamide cause drug dependence even though it acts on opioid receptors?
Loperamide is unable to accumulate behind the blood-brain barrier. The transporter protein P-glycoprotein actively pumps it back into the blood, so the drug does not reach CNS receptors and does not cause dependence.
How does codeine affect gastrointestinal motility?
It increases the tone of sphincters and smooth muscle, enhances spasmodic (segmental) motility, while suppressing propulsive peristalsis. As a result, chyme transit is slowed down.
What is the main feature of nufenoxole's action?
Unlike drugs that primarily affect motility, nufenoxole focuses on water-electrolyte metabolism. It actively inhibits the secretion of water and salts into the intestinal lumen and enhances their reabsorption.
Why is methylnaltrexone used in gastroenterology?
The drug is used to treat constipation in cancer patients receiving palliative therapy with narcotic analgesics. It eliminates the side effects of opioids on the intestine while preserving their central analgesic effect.
What else to study on this topic
- The role of P-glycoprotein in drug pharmacokinetics
- Comparative characteristics of propulsive and segmental intestinal motility
- Mechanisms of development of opioid-induced constipation
- Physiology of water-electrolyte balance in the lumen of the small and large intestine
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Antidiarrheal agents" and 5,304 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section «Drugs Affecting Digestive System Functions»
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.